Comparison Between Propess and Cook Double-balloon Catheter for Cervical Priming
Comparison Between Propess (Dinoprostone Controlled Release Pessary) and Cook Double-balloon Catheter for Cervical Priming: a Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Yin Fong Leung, MBBS
- Phone Number: 852 22554517
- Email: lyf971@hku.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Queen Mary Hospital
-
Contact:
- Yin Fong Leung, MBBS
- Phone Number: (852)-2255-4517
- Email: yin_fong18@yahoo.com.hk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Viable singleton pregnancy
- Cephalic presentation
- Bishop score <7
- At term (>=37+0 weeks of gestation)
- Nulliparous women
Exclusion Criteria:
- Gestation <37weeks
- Multiple pregnancy
- Bishop score <7
- Malpresentation
- Contraindication to vaginal delivery
- Previous Caesarean section
- History of myomectomy
- Maternal fever
- Suspected infection
- Abnormal fetal heart-rate patterns
- Rupture of membranes
- Intrauterine growth restriction
- Not fit for giving consent
- Allergic to Propess or PGE2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Cook double-balloon catheter
Participant is placed in lithotomy position, then to clean vulval and vaginal area, followed by inserting vaginal speculum.
Cook double-balloon catheter will be inserted under standard technique.
Doctor or midwife guide the cervical ripening balloon with stylet to pass through the cervix.
Uterine balloon should be place above level of internal os, then to remove the stylet before further advancing the catheter.
Cook double-balloon catheter is further advancing through the cervix until both balloons entered cervical canal.
Uterine and vaginal balloons are both inflated with up to 80ml normal saline according to manufacturer recommendation.
Maximal duration of balloon placement will be 12 hours.
If cervix remains unfavorable after Cook double-catheter balloons, she will be given another Cook double-catheter balloons priming the next day.
If cervix remains unfavourable after two balloon priming, elective Caesarean section will be advised.
|
To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval
|
|
Placebo Comparator: Propess
Participant will be firstly confirmed reactive tracing and without regular contraction by non-stress test for 20mins.
Propess will be checked its integrity and applied with lubricating jelly before insertion.
Propess is inserted to the posterior vaginal fornix.
Woman should inform medical staff if they have leaking sensation.
After insertion, woman will be advised to lie down and perform non-stress test for 2 hours.
Propess will be removed after 24 hours post insertion.
Cervical assessment is performed the next day after removal of Propess.
Patient with favourable cervix, i.e.
Bishop score >= 7, will start artificial rupture of membrane and syntocinon infusion.
Patient with unfavorable cervix, i.e.
Bishop score <7 is arranged another day of priming by PGE2.
If the cervix remains unfavorable after 2 days of pharmacological priming, women will be given a rest day or continued priming by Cook double-balloon catheter.
|
To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Priming to delivery interval
Time Frame: 1 year
|
Time for priming (device placement) to delivery interval
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vaginal delivery within 24 hours after priming
Time Frame: 1 year
|
delivery within 24 hours
|
1 year
|
|
Caesarean section rate
Time Frame: 1 year
|
need of resort to Caesarean section and the corresponding indication
|
1 year
|
|
Vaginal delivery rate
Time Frame: 1 year
|
included instrumental delivery, e.g.
vacuum extraction, forcep delivery
|
1 year
|
|
Priming to induction interval
Time Frame: 1 year
|
Time from priming to induction
|
1 year
|
|
Need of induction with oxytocin
Time Frame: 1 year
|
Chance of going into spontaneous labor after priming
|
1 year
|
|
Amount of oxytocin use
Time Frame: 1 year
|
calculate the amount of oxytocin use
|
1 year
|
|
Malpresentation after priming
Time Frame: 1 year
|
to confirm if cephalic presentation before start of induction
|
1 year
|
|
Failed induction rate
Time Frame: 1 year
|
defined as cervix failed to dilate to more than 3cm after 12 hours use of oxytocin
|
1 year
|
|
Uterine hyperstimulation
Time Frame: 1 year
|
defined by a single contraction lasting for more than 2 minutes or more than 5 contractions in 10 minutes for 30 minutes
|
1 year
|
|
Suspected intrauterine infection rate
Time Frame: 1 year
|
infection rate that require antibiotics treatment
|
1 year
|
|
Primary postpartum haemorrhage
Time Frame: 1 year
|
Blood loss >500ml within 24 hours of delivery
|
1 year
|
|
Length of hospital stay
Time Frame: 1 year
|
calculate length of hospital stay after delivery
|
1 year
|
|
Maternal satisfaction with the procedure
Time Frame: 1 year
|
on a visual analogue scale to rate maternal satisfaction of from 1 to 5, 5 is better, 1 is worse
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yin Fong Leung, MBBS, The University of Hong Kong
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UW 24-172
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.